Literature DB >> 31345644

Elimination of hepatitis C virus infection among people who use drugs: Ensuring equitable access to prevention, treatment, and care for all.

Jason Grebely1, Behzad Hajarizadeh2, Jeffrey V Lazarus3, Julie Bruneau4, Carla Treloar5.   

Abstract

There have been major strides towards the World Health Organization goal to eliminate hepatitis C virus (HCV) infection as a global public health threat. The availability of simple, well-tolerated direct-acting antiviral therapies for HCV infection that can achieve a cure in >95% of people has provided an important tool to help achieve the global elimination targets. Encouragingly, therapy is highly effective among people receiving opioid agonist therapy and people who have recently injected drugs. Moving forward, major challenges include ensuring that new infections are prevented from occurring and that people who are living with HCV are tested, linked to care, treated, receive appropriate follow-up, and have equitable access to care. This editorial highlights key themes and articles in a special issue focusing on the elimination of HCV among people who inject drugs. An overarching consideration flowing from this work is how to ensure equitable access to HCV treatment and care for all. This special issue maps the field in relation to: HCV prevention; the cascade of HCV care; strategies to enhance testing, linkage to care, and treatment uptake; and HCV treatment and reinfection. In addition, papers draw attention to the 'risk environments' and socio-ecological determinants of HCV acquisition, barriers to HCV care, the importance of messaging around the side-effects of new direct-acting antiviral therapies, the positive transformative potential of treatment and cure, and the key role of community-based drug user organizations in the HCV response. While this special issue highlights some successful efforts towards HCV elimination among people who inject drugs, it also highlights the relative lack of attention to settings in which resources enabling elimination are scarce, and where elimination hopes and potentials are less clear, such as in many low and middle income countries. Strengthening capacity in areas of the world where resources are more limited will be a critical step towards ensuring equity for all so that global HCV elimination among PWID can be achieved.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Access; Care; Drug users; HCV; Injecting; PWID; Treatment

Mesh:

Substances:

Year:  2019        PMID: 31345644     DOI: 10.1016/j.drugpo.2019.07.016

Source DB:  PubMed          Journal:  Int J Drug Policy        ISSN: 0955-3959


  10 in total

1.  Health care utilization and costs associated with direct-acting antivirals for patients with substance use disorders and chronic hepatitis C.

Authors:  Xinyi Jiang; Scott Martin Vouri; Vakaramoko Diaby; Weihsuan Lo-Ciganic; Robert Parker; Haesuk Park
Journal:  J Manag Care Spec Pharm       Date:  2021-10

2.  Substance Use Disorder Treatment Providers' Knowledge and Opinions Toward Testing and Treatment of Chronic Hepatitis C in Rural North Carolina.

Authors:  Donna M Evon; Christopher B Hurt; Delesha M Carpenter; Sarah K Rhea; Caitlin M Hennessy; William A Zule
Journal:  Rural Ment Health       Date:  2022-02-03

Review 3.  Future destinations and social inclusion scoping review: how people cured of hepatitis C (HCV) using direct- acting antiviral drugs progress in a new HCV-free world.

Authors:  Sarah R Donaldson; Andrew Radley; John F Dillon
Journal:  Subst Abuse Treat Prev Policy       Date:  2022-06-08

Review 4.  Comment on review article: Chronic hepatitis C virus infection cascade of care in pediatric patients.

Authors:  Nouhoum Bouare; Mamadou Keita; Jean Delwaide
Journal:  World J Gastroenterol       Date:  2022-04-14       Impact factor: 5.374

5.  Economic Evaluation of Hepatitis C Treatment Extension to Acute Infection and Early-Stage Fibrosis Among Patients Who Inject Drugs in Developing Countries: A Case of China.

Authors:  Yin Liu; Hui Zhang; Lei Zhang; Xia Zou; Li Ling
Journal:  Int J Environ Res Public Health       Date:  2020-01-28       Impact factor: 3.390

6.  A qualitative study of perceived barriers to hepatitis C care among people who did not attend appointments in the non-urban US South.

Authors:  Jacqueline E Sherbuk; Alexa Tabackman; Kathleen A McManus; Terry Kemp Knick; Julie Schexnayder; Tabor E Flickinger; Rebecca Dillingham
Journal:  Harm Reduct J       Date:  2020-09-18

7.  Against All Odds? Addiction History Associated with Better Viral Hepatitis Care: A Dutch Nationwide Claims Data Study.

Authors:  Daan W Von den Hoff; Floor A C Berden; Femke Atsma; Arnt F A Schellekens; Joost P H Drenth
Journal:  J Clin Med       Date:  2022-02-21       Impact factor: 4.241

8.  Randomized clinical trial: Direct-acting antivirals as treatment for hepatitis C in people who inject drugs: Delivered in needle and syringe programs via directly observed therapy versus fortnightly collection.

Authors:  Lewis Beer; Sarah Inglis; Amy Malaguti; Christopher Byrne; Christian Sharkey; Emma Robinson; Kirsty Gillings; Andrew Radley; Adrian Hapca; Brian Stephens; John Dillon
Journal:  J Viral Hepat       Date:  2022-05-26       Impact factor: 3.517

9.  A hepatitis C elimination model in healthcare for the homeless organization: A novel reflexive laboratory algorithm and equity assessment.

Authors:  A Seaman; C A King; T Kaser; A Geduldig; W Ronan; R Cook; B Chan; X A Levander; K C Priest; P T Korthuis
Journal:  Int J Drug Policy       Date:  2021-07-27

10.  Opportunistic treatment of hepatitis C virus infection (OPPORTUNI-C): study protocol for a pragmatic stepped wedge cluster randomized trial of immediate versus outpatient treatment initiation among hospitalized people who inject drugs.

Authors:  H Midgard; A K Finbråten; K B Malme; R M Berg-Pedersen; L Tanum; I C Olsen; R Bjørnestad; O Dalgard
Journal:  Trials       Date:  2020-06-15       Impact factor: 2.279

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.